Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
02/2010
02/04/2010US20100029712 Irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis
02/04/2010US20100029705 Administering an aminoindanyl derivative and; a steroid, dopamine receptor agonist or an anticholinergic or antimuscarinic agent; respiratory system disorders, antiallergens, chronic obstructive pulmonary disease, adult respiratory distress syndrome, bronchitis
02/04/2010US20100029702 Method For Identification of Compound Having Anti-Anxiety Effect
02/04/2010US20100029701 Macrocyclic spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
02/04/2010US20100029697 Substituted pyrido[3,2-e][1,2,4]triazolo[4,3-c]pyrimidine derivatives as cannabinoid-1 receptor modulators
02/04/2010US20100029691 Fast onset orodispersable tablets
02/04/2010US20100029689 Phosphodiesterase 4 inhibitors
02/04/2010US20100029685 Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators
02/04/2010US20100029684 Pyrazinone Modulator of Corticotropin-Releasing Factor Receptor Activity
02/04/2010US20100029665 Methods and Compositions for Treating Migraine Pain
02/04/2010US20100029658 Heterocyclic derivatives, pharmaceutical compositions and methods of use thereof
02/04/2010US20100029645 Inhibitors of Cytosolic Phospholipase A2
02/04/2010US20100029644 Compounds Which Modulate The CB2 Receptor
02/04/2010US20100029641 Aryl sulfamide derivatives and methods of their use
02/04/2010US20100029640 Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
02/04/2010US20100029639 Ion channel modulating compounds and uses thereof
02/04/2010US20100029631 Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient
02/04/2010US20100029629 Acyclic compounds having 5-ht6 receptor affinity
02/04/2010US20100029622 Microemulsions
02/04/2010US20100029620 Substituted triazoline, tetrazolone and imidazolone derivatives for use as a medicine
02/04/2010US20100029618 Alpha-2 receptor pan agonist and anticonvulsant compositions for treating chronic pain
02/04/2010US20100029617 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulene derivatives as orexin receptor antagonists
02/04/2010US20100029609 Biaryl sulfonamide derivatives
02/04/2010US20100029608 Histamine H3 Receptor Agents, Preparation and Therapeutic Uses
02/04/2010US20100029607 Substituted Piperazines as CB1 Antagonists
02/04/2010US20100029606 Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
02/04/2010US20100029603 16alpha-methyl or ethyl substituted estrogens
02/04/2010US20100029600 Dihydro-triterpenes in the treatment of viral infections, cardiovascular disease, inflammation, hypersensitivity or pain
02/04/2010US20100029599 Indolylamides as modulators of the EP2 receptor
02/04/2010US20100029598 Extended Benzamide Derivatives as Modulators of the EP2 Receptor
02/04/2010US20100029589 4,5-dihydro-oxazol-2yl derivatives
02/04/2010US20100029575 N-Oxides of Kappa Receptor Peptides
02/04/2010US20100029562 hG31P Expression System
02/04/2010US20100029559 Method for achieving desired glial growth factor 2 plasma levels
02/04/2010US20100029484 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
02/04/2010US20100028447 Intranasal, Buccal, And Sublingual Administration Of Metanicotine Analogs
02/04/2010US20100028445 Polymer
02/04/2010US20100028441 Compositions and methods for treating multiple sclerosis
02/04/2010US20100028440 Drying of drug-containing particles
02/04/2010US20100028429 Salts of potassium atp channel openers and uses thereof
02/04/2010US20100028426 Time-specific delayed/pulsatile release dosage forms.
02/04/2010US20100028370 Megalin-based delivery of therapeutic compounds to the brain and other tissues
02/04/2010US20100028364 Inhibition of sox9 function in the treatment of proteoglycan-associated pathophysiological conditions
02/04/2010US20100028360 Methods for the modulation of brain progestagen signaling in the prevention and treatment of neurological disorders and neurodegenerative diseases
02/04/2010US20100028359 Antibodies to receptor of advanced glycation end products (rage) and uses thereof
02/04/2010US20100028356 Method of diagnosing a neurodegenerative disease
02/04/2010US20100028353 Anti-amyloid immunogenic compositions, methods and uses
02/04/2010US20100028351 Anti-amyloid antibodies, compositions, methods and uses
02/04/2010US20100028349 activates FGF receptors, regulates the growth and differentiation of cells within the liver, regulates other cell types following secretion from the liver, plays a role in liver chemotaxis, has an oncogenic activity, or serves as an antigen for generating antibodies; treating diabetes or obesity
02/04/2010US20100028340 Antibodies against the rgm a protein and uses thereof
02/04/2010US20100028320 Methods and Compositions for Inhibiting Diseases of the Central Nervous System
02/04/2010US20100028305 Methods for the treatment of lysosomal storage disorders
02/04/2010US20100028298 Interferon type i supporting compounds
02/04/2010US20100028296 Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease
02/04/2010US20100028292 Amphiphilic Polymer-Protein Conjugates and Methods of Use Thereof
02/04/2010US20100028257 Pharmaceutical compounds
02/04/2010CA2732575A1 Immunotherapy compositions for the treatment and prevention of amyloidosis
02/04/2010CA2732343A1 Selective inhibition of polyglutamine protein expression
02/04/2010CA2732266A1 Treating various disorders using trkb agonists
02/04/2010CA2732232A1 3',6-substituted indirubins and their biological applications
02/04/2010CA2731939A1 Buprenorphine analogs
02/04/2010CA2731405A1 1,6-dihydro-2h-3-oxa-6-aza-as-indacene compounds
02/04/2010CA2731403A1 Pyrrolidin-3-ylmethyl-amine as orexin antagonists
02/04/2010CA2731358A1 5/5-or 5/6-membered condensed ring cycloalkylamine derivative
02/04/2010CA2731209A1 Spiroaminodihydrothiazine derivatives
02/04/2010CA2731171A1 Pkc-activating compounds for the treatment of neurodegenerative diseases
02/04/2010CA2731165A1 Process for the preparation of o-desmethylvenlafaxine
02/04/2010CA2731164A1 Polymorphic form of rasagiline mesylate
02/04/2010CA2730774A1 Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists
02/04/2010CA2730709A1 Withania somnifera plant extract and method of preparation thereof
02/04/2010CA2730489A1 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
02/04/2010CA2730148A1 Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
02/04/2010CA2729288A1 Administration regime for nitrocatechols
02/04/2010CA2728096A1 Compound with serotoninergic activity, process for preparing it and pharmaceutical composition comprising it
02/04/2010CA2725791A1 Novel cholest-4-en-3-one oxime derivatives, pharmaceutical compositions containing same, and preparation method_______________________
02/03/2010EP2149584A1 Method for enhancing immune response with peptide
02/03/2010EP2149575A1 Diazabicyclic compounds as opioid receptor agonists
02/03/2010EP2149573A1 Substituted indole sulfonamide compounds their preparation and use as medicaments
02/03/2010EP2149568A1 Aryl-sulphonamidic dimers as metalloproteases inhibitors
02/03/2010EP2149562A1 method of preparing (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride hemihydrate
02/03/2010EP2149560A1 1-substituted tetrahydroisoquinoline compound
02/03/2010EP2149553A1 3', 6-substituted indirubins and their biological applications
02/03/2010EP2149380A1 Veterinary immunotherapy compositions for the Aged Related Cognitive Dysfunction.
02/03/2010EP2149373A1 5HT7 receptor ligands and compositions comprising the same
02/03/2010EP2149370A1 Diazabicyclic compounds and microemulsions thereof
02/03/2010EP2148879A1 Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists
02/03/2010EP2148873A1 4-alkoxypyridazine derivatives as fast dissociating dopamine 2 receptor antagonists
02/03/2010EP2148872A1 Pyridine derivatives as fast dissociating dopamine 2 receptor antagonists
02/03/2010EP2148868A1 Novel aromatic heterocyclic carboxylic acid amide derivatives useful as potassium channel modulators
02/03/2010EP2148866A2 Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases
02/03/2010EP2148864A2 Fused-ring heterocycle opioids
02/03/2010EP2148862A1 Dihydroquinone and dihydronaphthridine inhibitors of jnk
02/03/2010EP2148857A1 Pyrrolidine derivatives as dual nk1/nk3 receptor antagonists
02/03/2010EP2148699A1 Vaccination regimen for b-cell vaccines
02/03/2010EP2148691A2 Local complement inhibition for treatment of complement-mediated disorders
02/03/2010EP2148670A1 Titration of tapentadol
02/03/2010EP2148669A1 Tapentadol for treating pain from arthritis
02/03/2010EP1917017B1 Treatment of amyotrophic lateral sclerosis with pyrimethamine and analogues
02/03/2010EP1351679B1 Method and composition for the treatment of diabetic neuropathy
02/03/2010CN100586945C Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
1 ... 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 ... 1833